🎓

Free Preview Lesson

This lesson is free to view. Subscribe to unlock all 10 modules and 63 lessons.

subscriber@gdaypharmacist.com.au • subscriber@gdaypharmacist.com.au • subscriber@gdaypharmacist.com.au • subscriber@gdaypharmacist.com.au

1.1 Overview of the OPRA® Exam: Gateway to Australian Pharmacy Practice — Updated 11 May 2026

Last reviewed: 11 May 2026

Learning Objectives

Upon completion of this lesson, you will be able to:

  • Describe the OPRA® examination's purpose, structure, and role in the Australian pharmacy registration pathway.
  • Identify the five subject areas tested and their published blueprint weightings.
  • Explain who must take OPRA® (Knowledge Stream) versus the Competency Assessment of Overseas Pharmacists (CAOP — Competency Stream).
  • Distinguish what OPRA® tests (Australian therapeutic practice) from what is examined later in the Intern Written Exam (Australian legislative and practice-standard content).
  • Itemise the APC fees, English-language requirements, and registration steps that bracket the OPRA® attempt.
  • Map the full pathway from OPRA® pass through provisional registration, internship, and final general registration.
  • Apply evidence-based study strategies aligned to the published blueprint and the published cognitive-level distribution.

1. The Australian Pharmacy Registration Pathway in One Page

To register and practise as a pharmacist in Australia, internationally qualified pharmacists must complete a structured pathway administered jointly by the Australian Pharmacy Council (APC) and the Pharmacy Board of Australia under the Australian Health Practitioner Regulation Agency (AHPRA).

[Eligibility Check]                        A$810       APC
        ↓
[OPRA® Knowledge Examination]              A$2,245     120 MCQ / 150 min / Pearson VUE
        ↓
[English Language Test]                    ~A$455      IELTS Academic 7.0 (or equivalent)
        ↓
[Skills Assessment Outcome]                A$300       APC — post-exam document supporting
                                                       visa application and AHPRA provisional
                                                       registration (valid 3 years)
        ↓
[Provisional Registration]                 ~A$370–377  Pharmacy Board of Australia (AHPRA)
                                                       (verify current schedule)
        ↓
[Internship — 1,575 supervised hours]                  ~12 months full-time
                                                       (COVID-19 modification of 1,824
                                                       baseline; in effect until further notice)
        ↓
[Intern Written Exam]                      A$790       APC — 75 MCQ / 2 hr / restricted open
                                                       book (AMH + APF, physical copies only)
        ↓
[Intern Oral Exam (practice)]              A$415       AHPRA on behalf of Pharmacy Board —
                                                       three sections, ~35 min total
                                                       (verify current schedule)
        ↓
[General Registration]                     A$484/yr    Practise unsupervised
                                           (A$583 NSW)

Total APC fees (Knowledge Stream): A$3,355. This is $810 (Eligibility Check) + $2,245 (OPRA®) + $300 (Skills Assessment Outcome). All-in candidate cost across the full pathway, excluding visa, travel, and English test resits, typically ranges A$8,000–A$12,000.

Note on the $300 Skills Assessment Outcome. This is a post-exam fee for the document APC issues once you have passed OPRA®. You use it to support a visa application and to apply to the Pharmacy Board for provisional registration. It is valid for 3 years and is not paid before the exam.

2. What OPRA® Is — and What It Replaced

The Overseas Pharmacist Readiness Assessment (OPRA®) is the APC's standardised knowledge examination for internationally qualified pharmacists seeking AHPRA registration through the Knowledge Stream. It is delivered globally at Pearson VUE Professional Test Centres.

2.1 KAPS → OPRA® transition

  • The previous knowledge examination — Knowledge Assessment of Pharmaceutical Sciences (KAPS) — was retired after its November 2024 sitting.
  • OPRA® replaced KAPS from March 2025. The redesign aligned the exam with current Australian therapeutic practice (AMH, eTG), introduced more clinical-scenario items, and updated the blueprint weightings.
  • Candidates who had begun the pathway under KAPS but had not passed before the November 2024 sitting transitioned automatically to OPRA® eligibility.

Source: Australian Pharmacy Council, APC announces re-designed KAPS exam (2024) — https://www.pharmacycouncil.org.au/media-hub/APC-announces-re-designed-KAPS-exam/

2.2 Who takes OPRA® — and who doesn't

StreamExamEligible candidates
Knowledge StreamOPRA®Pharmacists qualified in countries other than Australia, Canada, Ireland, New Zealand, the United Kingdom, and the United States
Competency StreamCAOP®Pharmacists who (a) completed an approved pharmacy qualification (or approved adjudication process) in Canada, Ireland, the United Kingdom, or the United States, AND (b) are currently registered as a pharmacist in one of those countries
Trans-TasmanMutual recognitionNew Zealand-registered pharmacists

If you trained in India, Egypt, Pakistan, the Philippines, South Africa, Bangladesh, Nepal, Sri Lanka, Iran, Iraq, the GCC, or any country not listed above as Competency-Stream-eligible, OPRA® is your exam. South Africa was always a Knowledge Stream / OPRA® country — its 18 March 2026 removal was from the separate AHPRA English-language recognised-country list (see Section 5.4), not from the OPRA® cohort.

OPRA® does not test pharmacy-school knowledge from any single jurisdiction. It tests the biomedical, pharmaceutical, and clinical sciences underlying the practice of pharmacy in Australia and New Zealand at the standard expected of a graduate at the point of provisional registration. It does not test Australian-specific legislation or practice standards — those are tested later, in the Intern Written Exam (see Section 3.3 and Section 6).

3. Examination Structure (APC Published Blueprint)

3.1 Format specifications

ParameterSpecification
DeliveryComputer-based; Pearson VUE test centre
Total questions120 multiple-choice items
Scored items108 (90%); remaining 12 are unscored pilot items, evenly distributed across the five content areas, not identified to candidates
Question formatSingle best answer, four options (A–D)
Duration150 minutes (no scheduled break). Plus 5 min NDA + 10 min tutorial before, and 5 min feedback survey after — none of these counts toward exam time
Reference materialsClosed book. Non-programmable on-screen calculator provided
Sittings per year3 — March, July, November
Maximum attemptsNo limit. Each retake requires re-registration and payment of the A$2,245 exam fee in full
Standard settingEvidence-based psychometric standard-setting processes involving subject-matter experts; the passing score reflects the minimum standard for entry to supervised practice
Result formatPass / Fail. Failing candidates receive subject-area band feedback for retake planning. No numerical score is released.
Result releaseApproximately 4 weeks post-examination
Examination feeA$2,245 (GST inclusive)

Source: APC OPRA® Exam Guide (16 April 2026); APC Knowledge Stream skills assessment outcome page; Pearson VUE delivery confirmation.

Common candidate trap. Coaching providers often quote "65–70% to pass". APC does not publish a numerical pass mark. The standard is set per session through expert-panel processes and the underlying raw-score equivalent varies. Plan to demonstrate genuine competence, not to chase a target percentage.

3.2 Subject-Area Blueprint (Official Weightings)

OPRA® content is sampled from five subject areas in the proportions below. Therapeutics and patient care dominates the exam — plan your study time accordingly.

Subject areaWeightingTypical content
Therapeutics and patient care45%Cardiovascular, endocrine, respiratory, infectious diseases, mental health, pain, GI, renal, women's and men's health; eTG and AMH application; dose calculations; special populations; harm minimisation; health promotion; confidentiality and professionalism
Biomedical sciences20%Anatomy, physiology, pathophysiology, medical microbiology, immunology, fluid/electrolyte/acid–base disorders
Pharmacology and toxicology15%Mechanisms of action, drug classes, receptor theory, adverse-effect profiles, drug interactions, toxicology and antidotes
Medicinal chemistry and biopharmaceutics10%Drug structure–activity relationships, formulation, stability, solubility, dosage form properties, pharmaceutical microbiology
Pharmacokinetics and pharmacodynamics10%ADME, bioavailability and bioequivalence, half-life, clearance, dosing in renal/hepatic impairment, therapeutic drug monitoring

Source: APC OPRA® Exam Guide (16 April 2026), section "Exam content".

Two area names worth memorising correctly. Many third-party study guides truncate these. The 45% area is "Therapeutics and patient care" — not "Therapeutics" alone — and the "and patient care" content (harm minimisation, confidentiality, special populations, health promotion) is examinable. The 10% area paired with PK is "Pharmacodynamics", not "Biopharmaceutics" (biopharmaceutics is grouped with medicinal chemistry).

3.3 What OPRA® tests in Australian context — and what it doesn't

This is the most consequential distinction in this lesson, because many candidates over-prepare for material that is not on OPRA®.

APC's exam guide states explicitly:

The OPRA® exam does not examine pharmacy practice issues specific to the Australian or NZ context such as legislation or practice standards. These are examined in later assessments included in the internship period as a successful candidate moves towards general registration.

Australian context that IS in OPRA® (because it shapes therapeutic decisions):

  • Therapeutic Guidelines (eTG) as the first-line evidence base for clinical scenarios.
  • Australian Medicines Handbook (AMH) for dosing, monitoring, interactions, contraindications.
  • TGA-approved drug nomenclature — drug names appear as per the TGA list of approved names.
  • TGA paediatric safety positions, including the 2012 position that OTC cough and cold medicines should not be used in children under 6 years (use in this age group is off-label) and should only be used in children aged 6–11 on the advice of a doctor, pharmacist, or nurse practitioner. The position applies to OTC cough and cold medicines generally, not only combination preparations.
  • Cultural responsiveness and patient communication as part of safe clinical practice — including use of professional interpreter services where language is a barrier to informed consent.
  • Special-population considerations in pregnancy, breastfeeding, paediatrics, and the elderly, framed against Australian therapeutic guidance.

Australian context that is NOT in OPRA®, but IS in the Intern Written Exam:

  • PBS / RPBS authority requirements, streamlined codes, Section 100, safety net thresholds, Closing the Gap PBS co-payment specifics.
  • Medicines scheduling rules — S2, S3, S4, S8 supply, recording, and storage requirements with state and territory variation.
  • AHPRA and Pharmacy Board of Australia registration standards, Code of Conduct, mandatory notifications, recency of practice.
  • State and territory real-time prescription monitoring systems — SafeScript (Vic, NSW), QScript (Qld), ScriptCheck SA, Tasmania DAPIS, WA RTPM.
  • Medicinal cannabis Special Access Scheme Category B and Authorised Prescriber pathways and S8 handling rules.
  • Pharmacist immuniser scope by state and territory regulation.

If you study this second list as if it were OPRA® content, you will use study time inefficiently. Most of it becomes critical six months from now, during the internship. For OPRA®, it is enough to recognise that the Australian system has these structures and that they will be examined later.

3.4 Cognitive-level distribution (Bloom and Anderson classification)

APC publishes the cognitive levels and their proportions, derived from the Bloom and Anderson classification:

Cognitive levelDefinitionProportion
Recall / RememberingRecalling or recognising specific information — facts, principles, terminology, interactions, protocols55%
Comprehension / UnderstandingCommunicating a concept or principle in a different form; classifying or comparing30%
ApplicationUsing methods and principles to solve a clinical or professional problem15%

Source: APC OPRA® Exam Guide (16 April 2026), "Question construction".

The marketing language around OPRA® emphasises clinical reasoning, but more than half the exam tests recall. Build factual fluency before drilling case scenarios.

3.5 Question-construction conventions APC publishes

Useful to internalise before the first practice paper:

  • Drug and ingredient names appear as per the TGA list of approved names.
  • Units follow the approved abbreviations from the Recommendations for terminology, abbreviations and symbols used in medicines documentation.
  • Values are presented in SI (metric) units.
  • Determiners are bold and CAPITALISED to draw attention to the kind of response expected: CORRECT, MOST, LEAST, NOT.

If you trip on a hard item, look back at the determiner first. Many wrong answers come from candidates picking the true statement when the question asked for the MOST appropriate, or picking the obvious treatment when the stem said which to AVOID.

4. Sample Questions with Worked Rationales

Two representative items in OPRA® format. Read the stem, attempt the item, then study the rationale.

Sample Question 1 — Direct Clinical Application

A 68-year-old man with non-valvular atrial fibrillation and type 2 diabetes presents for routine warfarin monitoring. His INR is 5.2. He reports no bleeding, no recent trauma, no surgery, and no planned invasive procedure. His current warfarin dose is 4 mg daily. What is the MOST appropriate immediate action?

A. Cease warfarin and administer vitamin K 1 mg orally
B. Cease warfarin for 1–2 doses and recheck INR within 24–48 hours
C. Continue current dose and recheck INR in 1 week
D. Reduce warfarin dose by 50% immediately

Correct answer: B.

Rationale. Per Therapeutic Guidelines: Cardiovascular (current edition), management of supratherapeutic INR depends on the INR magnitude and whether bleeding or high bleeding risk is present.

ScenarioRecommended action
INR 4.5–10, no bleeding, no high-risk featuresWithhold 1–2 warfarin doses; recheck INR within 24–48 h; resume at a lower maintenance dose once INR <5
INR 4.5–10 with high bleeding riskAs above, plus vitamin K 1–2 mg orally
INR >10, no bleedingVitamin K 3–5 mg orally
Any INR with major bleedingVitamin K 5–10 mg IV plus prothrombin complex concentrate (or FFP if PCC unavailable)

This patient has INR 5.2 with no bleeding and no high-risk features in the stem, so vitamin K (option A) is not yet indicated. Option C is unsafe — continuing supratherapeutic anticoagulation. Option D under-corrects without first confirming response. B is the eTG-aligned action.

OPRA® skills tested: therapeutic guideline application, risk stratification, eTG-aligned anticoagulation management.

Sample Question 2 — Cultural Safety + Clinical Assessment

A mother requests "something for fever and cough" for her 3-year-old daughter. Symptoms have lasted 2 days; temperature is 38.5 °C. The family arrived from India three weeks ago, and the mother has limited English proficiency. Which approach BEST demonstrates safe, culturally responsive pharmacy practice?

A. Recommend paracetamol and refer to a GP if symptoms persist beyond 48 hours
B. Engage TIS National (Translating and Interpreting Service) and conduct a structured paediatric symptom assessment before recommending therapy
C. Provide written consumer medicine information in multiple languages
D. Recommend a children's combination cough-and-cold preparation for symptomatic relief

Correct answer: B.

Rationale.

  • A is partially correct — paracetamol is appropriate for paediatric fever and a GP referral is reasonable — but it bypasses the language barrier and risks missing red flags (respiratory distress, dehydration, prolonged fever, recent travel exposures including arboviral or enteric infections).
  • B addresses both the cultural-safety obligation (genuine informed consent and accurate history-taking require shared language; TIS National is free for community pharmacy use) and the clinical-assessment imperative for a febrile under-5. Only this option does not skip a step.
  • C is helpful but insufficient on its own — written CMI does not substitute for interactive history-taking.
  • D is incorrect. The TGA's 2012 position is that OTC cough and cold medicines (which include combination preparations as well as single-active products) should not be used in children under 6 years, citing safety concerns and limited evidence of efficacy. In children aged 6–11, OTC cough and cold medicines should only be used on the advice of a doctor, pharmacist, or nurse practitioner. This is a high-yield Australian-context fact and a recurrent OPRA® distractor.

OPRA® skills tested: patient-care reasoning, paediatric over-the-counter safety, TGA paediatric cough-and-cold guidance, recognition of communication-barrier mitigation as a clinical (not optional) step.

5. English-Language Requirements

AHPRA's English Language Skills Registration Standard applies to all pharmacist registration applications. Score requirements changed on 23 April 2026. Verify which table applies to your test sit-date.

5.1 Tests sat on or BEFORE 22 April 2026

TestOverallLRWS
IELTS Academic7.07.07.06.57.0
OET—BBC+B
PTE Academic6666665666
TOEFL iBT9424242423
Cambridge C1 Advanced185185185176185
Cambridge C2 Proficiency185185185176185

5.2 Tests sat on or AFTER 23 April 2026 (current)

TestOverallLRWS
IELTS Academic7.07.07.06.57.0
OET (numeric)—350360350360
PTE Academic6358596076
TOEFL iBT9122222324
Cambridge C1 Advanced178175179180194
Cambridge C2 Proficiency185185185176185

5.3 Behavioural traps in the new tables

  • IELTS Academic is unchanged across both tables. IELTS candidates are unaffected by the 23 April 2026 transition.
  • PTE Academic Speaking jumped 66 → 76 — the largest single component change across all five tests. Plan additional preparation if PTE is your test.
  • PTE Academic Writing went 56 → 60 — a smaller but real increase.
  • OET letter grades are retired for AHPRA purposes from 23 April 2026. AHPRA now reads numerical scores; the historic "B in all four" no longer suffices because Reading and Speaking now require 360.
  • Cambridge C1 Advanced now has differentiated component scores for the first time; Speaking sits significantly higher (194) than Listening (175) and Reading (179).
  • Cambridge C2 Proficiency is unchanged — the only test where every component stayed identical.
  • Test result validity: 2 years from the sit date.
  • Two sittings within 12 months may be combined, provided each component meets the AHPRA floor scores.
  • IELTS One Skill Retake is accepted by AHPRA as part of the original sitting (not a second sitting). Candidates may re-sit a single component within 60 days of the original test date. Useful where one component (commonly Writing) falls below the floor while the others meet it.
  • All tests must be sat at approved physical centres. At-home and online versions are not accepted (with the narrow exception of OET's computer-based-at-test-centre format).

5.4 Recognised-country exemption

Pharmacists who completed their primary qualification entirely in English at a recognised institution in Australia, Canada, Ireland, New Zealand, the United Kingdom, or the United States may be exempt from the English-test requirement.

South Africa is no longer a recognised country. It was removed from the recognised-country list with effect from 18 March 2026, following a 12-month transition period under the revised English Language Skills Registration Standard. Applicants who lodged a complete AHPRA application before 18 March 2026 had their application assessed under the prior arrangement; those lodging on or after that date must demonstrate English through an accepted test. Verify the current list against the AHPRA Accepted English language tests page on the day of application.

Source: AHPRA, Accepted English language tests — https://www.ahpra.gov.au/Registration/Registration-Standards/English-language-skills/Accepted-English-language-tests.aspx; AHPRA Transition Arrangements Policy (effective 23 April 2026).

6. After OPRA®: The Internship and Final Registration

Passing OPRA® is the mid-point, not the finish line.

6.1 Skills Assessment Outcome and provisional registration

  • After passing OPRA®, request the Skills Assessment Outcome from APC (A$300). This is the document you use to support your visa application and your AHPRA provisional registration application. It is valid for 3 years.
  • Apply for provisional registration via the AHPRA online portal. Provisional registration permits supervised practice only.
  • Required documents: APC OPRA® pass letter and Skills Assessment Outcome, English test certificate, identity, criminal-history check, professional-indemnity insurance, recency-of-practice declaration.
  • Fee: approximately A$370–377 (application + first-period registration). Verify current schedule on the AHPRA fees page.

6.2 Internship — supervised practice hours

  • Typically completed full-time over ~12 months (or part-time over up to 4 years).
  • Must be served at an APC- and Pharmacy-Board-approved training site under an approved Preceptor.
  • Combines structured workplace experience, formal assessments, and Continuing Professional Development hours.
  • Concurrent enrolment in an Intern Training Program (ITP) is required — typically PSA (community-focused) or SHPA (hospital-focused) depending on practice setting. The ITP is a separate enrolment with separate fees.

Hours requirement — read carefully. The Pharmacy Board's Registration standard: Supervised practice arrangements sets the requirement at 1,824 hours. From 30 April 2020, in response to the COVID-19 pandemic, the Board reduced this to 1,575 hours. The Board states the modification "remains in effect until further notice." Plan around 1,575 hours for now, but verify the current requirement on the day of provisional registration in case the modification has been rescinded. The 2024–2025 APOE-60 oral exam application form continues to reference 1,824 as the standard with the modification noted, so both numbers will appear in official paperwork.

6.3 Intern Written Exam

  • Conducted by APC.
  • 75 items. From January 2026, calculation questions are Fill-in-the-Blank (FIB) format — exact numerical answers as directed are required, with no partial credit; the remaining items are multiple-choice.
  • 2 hours.
  • Restricted open book. You may bring one original paper copy each of the Australian Medicines Handbook (AMH) and the Australian Pharmaceutical Formulary and Handbook (APF). Small sticky flags are permitted (max ≈12 mm × 44 mm); oversized tabs, bookmarks, and adhesive notes are not. No digital references, no notes, no loose papers, no printed PDFs, no annotations of any kind inside the books.
  • Fee: A$790 per attempt.
  • Tests applied therapeutics and dispensing law in clinical scenarios.
  • Pass valid for 18 months — you must pass the Intern Oral Exam within that window (and vice versa: an oral pass requires the written within 18 months as well).

6.4 Intern Oral Exam (practice)

  • Conducted by AHPRA on behalf of the Pharmacy Board of Australia. The Intern Training Program (PSA or SHPA) does not run this exam, even though candidates often confuse the two — PSA / SHPA run the ITP enrolment and curriculum.
  • Three parts, approximately 35 minutes total (reduced from 4 parts / 45 minutes effective 1 January 2021):
    1. Primary Healthcare (Part A) — role-play of an OTC scenario in which a patient or carer requests assistance with a self-treatable condition; the candidate provides assessment, OTC recommendation, and referral where indicated. No reference materials permitted.
    2. Legal and Professional Practice (Part B) — legislation, ethics, and professional standards. No reference materials permitted.
    3. Problem Solving and Communication (Part C) — prescription problems, drug interactions, and professional decisions, conducted as a role-play in which the candidate is the pharmacist and the examiner plays the patient (or carer) and/or the prescriber.
  • Reference materials are permitted in Part C only — AMH, APF, and eTG. No other references (including AusDI) are accepted. Verify against the current Pharmacy oral examination (practice) candidate guide (April 2025).
  • Three exam periods per year — broadly February, June, and October. Each period runs for several weeks within the relevant month; application windows close several weeks before each period. Candidates are randomly allocated a date and time within the period after applications close, and notified by email approximately two weeks before commencement.
  • Eligibility: provisional registration, completion of 75% of supervised practice hours by the exam period commencement date, enrolment in an ITP, and CPD compliance.
  • Fee: A$415 (verify against the current candidate guide).

6.5 General registration

  • Apply to AHPRA on completion of internship and both intern exams.
  • Annual fee: A$484 standard (or A$583 in New South Wales, inclusive of the Pharmacy Council of NSW complaints component) — period 1 December 2025 to 30 November 2026.
  • Permits unsupervised practice across all Australian states and territories.
  • Subject to 40 CPD credits per year (CPD cycle 1 October – 30 September), of which Group 1 (knowledge acquisition without assessment) is capped at 20 credits — i.e., at least 20 credits must come from Group 2 (assessed learning, 2 credits per hour) and/or Group 3 (practice-improvement activities with reflection, 3 credits per hour). CPD compliance is declared at registration renewal (due 30 November annually) per the Pharmacy Board Continuing Professional Development Registration Standard.

7. APC Quality Assurance and Standard Setting

7.1 Item development

  • Items are written by panels of practising Australian and New Zealand pharmacists (community, hospital, and academic settings) trained in MCQ construction.
  • Each item undergoes peer review, clinical validation, and statistical analysis after pilot administration as one of the 12 unscored items.
  • Subject-area panels ensure blueprint coverage across sittings.

7.2 Standard setting

APC describes the process as "evidence-based psychometric standard-setting processes involving subject matter experts". APC does not publish the specific method by name. The expert-panel approach is consistent with criterion-referenced assessment design used internationally for licensing examinations.

The cut-score is set per session — there is no fixed pass mark across sittings, and no published numerical threshold.

7.3 Result reporting

  • Pass / Fail outcome only.
  • Failing candidates receive subject-area band feedback indicating relative performance across the five blueprint areas, supporting targeted retake preparation.
  • No numerical score is released. This is consistent with criterion-referenced assessment design and is a deliberate APC policy choice.
  • Results released approximately 4 weeks after the exam.

8. Strategic Preparation Framework

8.1 Time allocation matched to the blueprint

Subject areaBlueprint weightSuggested study time (12-week plan)
Therapeutics and patient care45%~5.5 weeks
Biomedical sciences20%~2.5 weeks
Pharmacology and toxicology15%~1.5 weeks
Medicinal chemistry and biopharmaceutics10%~1 week
Pharmacokinetics and pharmacodynamics10%~1.5 weeks (overlaps with calculation drilling)

8.2 Time allocation matched to the cognitive-level distribution

  • Recall (55%) — drug names, mechanisms, key adverse effects, common interactions, eTG first-line recommendations. Spaced repetition is the right tool here.
  • Comprehension (30%) — explain why a recommended therapy is recommended; classify drugs by class, mechanism, or indication; compare options.
  • Application (15%) — case-based reasoning under time pressure. This is the part that distinguishes prepared candidates from over-prepared candidates.

If you spend 80% of your prep on case scenarios, you under-invest in the 55% of the exam that rewards plain recall. Build the factual base first.

8.3 Primary Australian references (essential)

ResourceUse
Australian Medicines Handbook (AMH) — current annual editionFirst-line drug information, dosing, monitoring, interactions
Therapeutic Guidelines (eTG complete) — current online editionEvidence-based first-line therapy by clinical scenario
Australian Pharmaceutical Formulary and Handbook (APF 26) — 2024 editionDispensing reference; mostly examined later in the Intern Written Exam
APC OPRA® Exam Guide (16 April 2026) and sample paperOfficial format, blueprint, example items

8.4 Secondary references (high-yield supplementary)

  • Australian Prescriber — open-access drug evaluations and therapeutic reviews; now hosted by Therapeutic Guidelines Ltd following the 2022 NPS MedicineWise wind-down.
  • Australian Commission on Safety and Quality in Health Care (ACSQHC) — medication safety standards, high-risk medicine guidance.
  • Pharmaceutical Society of Australia (PSA) — practice guidelines, MedsCheck, vaccination, clinical interventions.
  • Society of Hospital Pharmacists of Australia (SHPA) — hospital practice standards.
  • TGA — adverse event reporting (DAEN), scheduling decisions (SUSMP), unapproved-product pathways, paediatric safety positions.

Note on NPS MedicineWise. NPS MedicineWise ceased operations on 31 December 2022. Its programmes and resources transferred to the Australian Commission on Safety and Quality in Health Care, the Department of Health and Aged Care, Therapeutic Guidelines Ltd (which now publishes Australian Prescriber), Australian Healthcare Associates (which now operates Medicines Line — 1300 MEDICINE), and the University of Tasmania (which delivers the National Prescribing Curriculum). References to "NPS" in older study materials remain clinically accurate, but the organisation no longer publishes new content. Use the successor sources above.

8.5 Active-learning techniques

  • Spaced repetition with active recall — Anki, Quizlet, or paper flashcards built directly from AMH and eTG content. Heavy weighting toward this for the 55% recall component.
  • Case-based reasoning — work through clinical scenarios using only AMH and eTG, then check rationale against the source.
  • Practice question volume — aim for 1,500+ Australian-context MCQs across the 12 weeks; review every wrong answer to root cause.
  • Mock examinations under timed conditions — at least three full 150-minute mocks in the final 4 weeks.
  • Calculation drilling — daily practice. OPRA® calculations sit within the 10% PK/PD area and the dose-calculation portion of the 45% therapeutics area, but errors here are decisive and almost always preventable.

9. Examination Day

9.1 Pre-examination

  • Arrive 30 minutes early. Pearson VUE will not admit late candidates.
  • Bring valid government-issued photo identification matching the name on your APC registration. A current passport is recommended for international candidates.
  • No personal items are permitted at the workstation. Lockers are provided.
  • 5-minute non-disclosure agreement and 10-minute software tutorial precede the exam — neither consumes exam time.

9.2 During the examination

  • 150 minutes for 120 questions ≈ 75 seconds per question average. Calculation and case items require more; recall items less.
  • No scheduled break. Optional unscheduled breaks are permitted, but the clock continues to run — most candidates complete the exam without breaking.
  • Flagging system — mark uncertain items and review at the end if time permits.
  • On-screen non-programmable calculator is available for calculation items.
  • Closed book — no reference materials, notes, watches, or electronic devices are permitted.

9.3 Post-examination

  • 5-minute exam feedback survey (does not affect your result).
  • Results in approximately 4 weeks via the APC portal.
  • Fail outcomes include subject-area band feedback for retake planning.
  • Pass outcomes entitle you to request the Skills Assessment Outcome and to apply for AHPRA provisional registration.

10. Question-Approach Technique — The READ Method

A reliable, time-efficient process for OPRA® items:

  • R — Read the stem fully before looking at options. Identify what is being asked, the patient's specific clinical context, and the determiner — APC bolds and CAPITALISES words like CORRECT, MOST, LEAST, and NOT specifically to help you here. Read it before you read the options.
  • E — Eliminate options that are clinically unsafe, contraindicated, or contradicted by AMH or eTG. Most items can be reduced to two plausible options within 30 seconds.
  • A — Apply the relevant guideline or rule. For OPRA®, ask: what does eTG / AMH say for this exact scenario? PBS or scheduling specifics are not what is being tested at this stage of the pathway.
  • D — Decide and record. Trust your first instinct unless a specific reason emerges to change it. Move on; do not dwell.

If an item is genuinely beyond your knowledge: eliminate what you can, choose the safest option, flag, and return at the end. There is no negative marking; every blank answer is a guaranteed lost mark.

11. Common Candidate Pitfalls

  1. Defaulting to home-country practice. Australian therapeutic guidelines often differ. The "right" first-line antihypertensive in your home jurisdiction may not be the eTG first-line.
  2. Memorising drug facts without clinical reasoning. OPRA® rewards application — the same drug fact will appear in different correct/incorrect roles depending on the patient.
  3. Studying PBS / scheduling / AHPRA legislation as if it were on OPRA®. It is not — it is on the Intern Written Exam later. Spending a third of your study time on PBS authority codes is wasted effort at this stage.
  4. Ignoring the "and patient care" half of the 45% area. Cultural responsiveness, harm minimisation, confidentiality, and special-population considerations are recurrent themes embedded across the 45%.
  5. Treating the exam as primarily applied reasoning. It isn't. 55% is recall. Build factual fluency before drilling cases.
  6. Neglecting calculation practice. Calculation errors are decisive and almost always preventable. Drill daily.
  7. Treating OTC cough and cold medicines as routine paediatric therapy. TGA's 2012 position: do not use in children under 6 years; use in children 6–11 only on advice of a doctor, pharmacist, or nurse practitioner. The position applies to cough and cold medicines generally, not only combination preparations — a recurrent OPRA® distractor.
  8. Confusing the exam open/closed-book rules. OPRA® is closed book. The Intern Written Exam (later in the pathway) is restricted open book — physical AMH and APF only. They prepare differently.
  9. Cramming the week before. Sleep, exercise, and consolidation in the final 7 days outperform last-minute new content.

12. Ten Core Principles for OPRA® Success

  1. Patient safety is the lens — every decision is judged on what is safest for this specific patient.
  2. Australian therapeutic guidelines are authoritative — eTG, AMH, TGA paediatric positions. Australian legislative content sits in the next exam, not this one.
  3. Blueprint-weighted study — 45% of your time on therapeutics and patient care is not optional; it is mathematics.
  4. 55% is recall — drill the facts before you drill the cases.
  5. Active practice beats passive reading — questions reveal your gaps; reading hides them.
  6. Cultural responsiveness is clinical practice — not a soft skill, not an add-on.
  7. Calculation discipline is non-negotiable — set up dimensional analysis every time.
  8. Time is a resource — 75 seconds per question is the budget; respect it.
  9. One difficult question is not the exam — flag and move; the next question is fresh marks.
  10. Provisional registration, not perfection, is the goal — competence to enter supervised practice.

Conclusion

OPRA® is a structured, blueprint-driven, criterion-referenced examination. It is challenging because Australian pharmacy practice demands competence — but its design is transparent, its content is sourceable, and its requirements are achievable through systematic preparation aligned to the published blueprint and the published cognitive-level distribution.

You are preparing not for a single exam, but for safe, evidence-based, culturally responsive practice in a complex healthcare system. Every hour invested in eTG application, AMH familiarity, and clinical-scenario reasoning is an investment in both passing OPRA® and practising well after.

The next lesson — 1.2 APC and the Pharmacy Board of Australia — covers the regulatory framework that sits behind OPRA® and structures your practice for the rest of your career.

Key Sources (verify on day of application — primary sources update without notice)

APC and Pharmacy Council

AHPRA and Pharmacy Board of Australia

Therapeutic and reference resources

  • Therapeutic Guidelines Limited. Therapeutic Guidelines (eTG complete). Melbourne: TG. (Subscription, current online edition.)
  • Australian Medicines Handbook Pty Ltd. Australian Medicines Handbook (current annual edition). Adelaide: AMH.
  • Pharmaceutical Society of Australia. Australian Pharmaceutical Formulary and Handbook (26th ed., 2024). Canberra: PSA.
  • Department of Health and Aged Care. Pharmaceutical Benefits Scheme (PBS) Schedule.

Safety and quality

Direct contacts

This lesson is exam-preparation guidance. All fees, dates, scores, and policy details should be verified against the primary sources listed above on the day of application or examination, as APC, AHPRA, and the Pharmacy Board update requirements without prior notice. Last reviewed 11 May 2026.

Next

1.2 APC and the Pharmacy Board of Australia: Regulatory Framework for Pharmacy Practice →